Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aclaris Therapts (NQ: ACRS )

3.800 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aclaris Therapts

< Previous 1 2 3 4 Next >
The Daily Biotech Pulse: Biogen Slumps As CMS Announces Restrictive Coverage For Aduhelm, Aclaris CMO Departs, Immuron Spikes On US Military Award
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Biogen Shares Slip On Restricted Coverage For Its Alzheimer's Drug Biogen... 
Via Benzinga
Looking Into Aclaris Therapeutics's Return On Capital Employed
Benzinga Pro data, Aclaris Therapeutics (NASDAQ:ACRS) reported Q3 sales of $1.66 million. Earnings fell to a loss of $20.30 million, resulting in a 12.71% decrease from last... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Leap Therapeutics (NASDAQ:LPTX) stock rose 32.64% to $2.56 during Thursday's pre-market session. The company's market cap stands at $152.7 million. Phio... 
Via Benzinga
Looking into Aclaris Therapeutics's Return on Capital Employed
After pulling data from Benzinga Pro it seems like during Q2, Aclaris Therapeutics's (NASDAQ:ACRS) reported sales totaled $1.82 million. Despite a 36.89% in earnings, the company... 
Via Benzinga
The Daily Biotech Pulse: Cellect Jumps On First Apograft Transplantation, AstraZeneca, European Commission Bury Legal Hatchet, Cassava Defends Itself
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 2) Abbott Laboratories (NYSE:... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Cara Therapeutics (NASDAQ:CARA) ... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers NuCana (NASDAQ:NCNA) shares moved upwards by 16.17% to $3.16 during Thursday's regular session. NuCana's stock is trading at a volume of 4.7 million shares... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021
Upgrades According to Raymond James, the prior rating for Welltower Inc (NYSE:WELL) was changed from Market Perform to Strong Buy. For the first quarter, Welltower had an... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Aethlon Medical (NASDAQ:AEMD) shares moved upwards by 347.96% to $9.9 during Wednesday's regular session. As of 12:30 EST, Aethlon Medical's stock is... 
Via Benzinga
The Daily Biotech Pulse: Lyra Gains On Positive Regulatory Outcome, FDA Nod For Pfizer's Prevnar Vaccine, Merck Inks COVID-19 Treatment Supply Deal With US
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 8) Agios Pharmaceuticals, Inc... 
Via Benzinga
Exposures COVID-19 Product Safety
75 Biggest Movers From Yesterday
Gainers Clover Health Investments, Corp. (NASDAQ: CLOV) shares surged 85.8% to close at $22.15 on Tuesday amid increased retail investor interest in the stock. NextDecade... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Aethlon Medical (NASDAQ:AEMD) sto... 
Via Benzinga
Mid-Afternoon Market Update: Crude Oil Rises Over 1%; Aclaris Therapeutics Shares Plunge
Toward the end of trading Tuesday, the Dow traded up 0.01% to 34,634.62 while the NASDAQ rose 0.29% to 13,921.88. The S&P also rose, gaining 0.04% to 4,228.15. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Cyclerion Therapeutics (NASDAQ:CYCN) stock increased by 37.46% to $4.33 during Tuesday's regular session. Trading volume for this security as of 12:30 EST is 9... 
Via Benzinga
Mid-Day Market Update: Coupa Software Drops After Q1 Results; NextDecade Shares Jump
Midway through trading Tuesday, the Dow traded down 0.09% to 34,598.11 while the NASDAQ rose 0.09% to 13,894.14. The S&P also fell, dropping 0.09% to 4,222.88. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
50 Stocks Moving In Tuesday's Mid-Day Session
Gainers Clover Health Investments, Corp. (NASDAQ: CLOV) shares jumped 72.4% to $20.55 amid increased retail investor interest in the stock. NextDecade Corporation (NASDAQ: NEXT... 
Via Benzinga
Aclaris' ATI-1777 Aces Atopic Dermatitis Trial with Minimal Systemic Exposure
Aclaris Therapeutics Inc (NASDAQ: ACRS) has announced preliminary topline results from its Phase 2a trial evaluating ATI-1777 for moderate to severe atopic... 
Via Benzinga
These 7 Medical Stocks Are Breaking Down — The Sell Rule You Should Know
Former high-flyers Dexcom and Tandem Diabetes are among seven health care stocks breaking down right now, according to MarketSmith.com. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For April 21, 2021
Upgrades For Cerecor Inc (NASDAQ:CERC), Maxim Group upgraded the previous rating of Hold to Buy. In the fourth quarter, Cerecor showed an EPS of $0.19, compared to $0.10... 
Via Benzinga
The Daily Biotech Pulse: Negative Regulatory Tidings For Provention Bio, Celcuity Soars On In-licensing Deal, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 8) Aclaris Therapeutics, Inc... 
Via Benzinga
The Daily Biotech Pulse: Immutep Extends Run, FDA Nod For Gilead, Merck, Bristol-Myers Squibb Release Late-Stage Cancer Immunotherapy Data
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 7) Aclaris Therapeutics, Inc... 
Via Benzinga
Exposures Product Safety
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.